Mandate

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

July 09, 2024 Banking and Finance

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.

As a result of the transaction, outstanding bonds in SBB in aggregate amounts of EUR 275,039,000, SEK 721,000,000 and NOK 40,000,000 were exchanged for new bonds in Sveafastigheter amounting to EUR 110,900,000 (under a framework of EUR 183,500,000) and SEK 412,500,000. In addition to the instrument exchange, SBB also offered, under certain conditions, a cash component as compensation for the exchange.

Danske Bank A/S, DNB Markets, part of DNB Bank ASA, Sweden branch and Skandinaviska Enskilda Banken AB (publ) acted as dealer managers in connection with the exchange offer.

Vinge's team consisted of Mikael Ståhl, Rikard Lindahl, Lionardo Ojeda, William Kåge, Benjamin Vafaeian, August Ahlin and Filip Magnusson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025